# A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult 

Source: https://onco.cc/trials/nct06568939/  
OnCo record `nct06568939` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Telisotuzumab vedotin in non-small-cell lung cancer and small-cell lung cancer, run by AbbVie, now recruiting.

## Summary

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT06568939 by AbbVie, with 150 participants planned, started 2025-01-20 and due to reach its primary completion in 2028-02. Interventions recorded: Telisotuzumab Vedotin. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06568939
- Phase: 2
- Setting: A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Sponsor: AbbVie
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT06568939: https://clinicaltrials.gov/study/NCT06568939

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Telisotuzumab vedotin](https://onco.cc/drugs/telisotuzumab-vedotin/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)

---
JSON: https://onco.cc/api/v1/entities/nct06568939.json